Rigen Biotech
Minhang
About Rigen Biotech
Rijing Biosciences has launched thyroid biopsy needles, multi-gene qPCR detection and NGS detection, Thyroscan® thyroid nodule benign and malignant classifier, and targeted surgery for thyroid cancer from preoperative sampling, diagnosis, to postoperative monitoring. Full-process series products such as post-recurrence monitoring provide a variety of solutions for the entire thyroid cancer diagnosis and treatment cycle.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Total funding: $29.8M
- Funding stage: Early Stage Venture
- Last round: Series B (Nov 2025)
- Website: rigen-bio.com
- Phone: 1-215-825-0316
Industries & Categories
Biotechnology, Health Diagnostics, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/rigen-biotech-89128 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.